Publications by authors named "A Crivaro"
Article Synopsis
- Gaucher Disease (GD) is a genetic condition caused by a deficiency in the enzyme glucocerebrosidase, and Velaglucerase alfa is used to replace this enzyme through therapy.
- Novel nanoparticle systems made from Eudragit have been developed to enhance the delivery and effectiveness of Velaglucerase alfa, demonstrating high stability and efficient encapsulation.
- In laboratory studies, these nanoparticles showed improved interaction with important proteins, better enzyme release in acidic conditions, and increased internalization in GD cells, leading to enhanced enzyme activity without affecting cell viability.
Bone marrow adipocytes alteration in an model of Gaucher Disease.
Mol Genet Metab Rep
September 2023
Gaucher disease (GD) is caused by biallelic pathogenic variants in gene that encodes the lysosomal enzyme glucocerebrosidase. Up to now, specific treatment for GD cannot completely reverse bone complications. Bone is composed of different cell types; including osteoblasts, osteocytes and osteoclasts.
View Article and Find Full Text PDFClostridioides difficile is a spore-forming anaerobe microorganism associated to nosocomial diarrhea. Its virulence is mainly associated with TcdA and TcdB toxins, encoded by their respective tcdA and tcdB genes. These genes are part of the pathogenicity locus (PaLoc).
View Article and Find Full Text PDFGaucher disease (GD) is caused by pathogenic mutations in GBA1, the gene that encodes the lysosomal enzyme β-glucocerebrosidase. Despite the existence of a variety of specific treatments for GD, they cannot completely reverse bone complications. Many studies have evidenced the impairment in bone tissue of GD, and molecular mechanisms of bone density alterations in GD are being studied during the last years and different reports emphasized its efforts trying to unravel why and how bone tissue is affected.
View Article and Find Full Text PDF